Response to vincristine of recurrent brain tumors in children.

Abstract

Seventeen children with clinical evidence of a recurrent brain tumor were treated with vincristine 1.5 mg/sq m weekly for 12 weeks with doses on alternate weeks thereafter. Eight of the 16 patients who received four or more doses of vincristine showed significant objective responses; these included patients with high-and low-grade astrocytomas and patients with medulloblastoma. Six of the eight who responded remained asymptomatic for more than 2 years. The toxicity encountered was minimal except for seizures possibly related to vincristine in three children, who were able to resume treatment. Vincristine therapy results in long-term regression in a wide variety of pediatric brain tumors and causes little or no toxicity.

• Authors: J G Rosenstock, A E Evans, L Schut
• Journal: Journal of neurosurgery (J Neurosurg) Vol. 45 Issue 2 Pg. 135-40 (Aug 1976) ISSN: 0022-3085 [Print] United States
• PMID: 939971 (Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Vincristine

Topics

• Astrocytoma (drug therapy)
• Brain Neoplasms (drug therapy)
• Child
• Child, Preschool
• Drug Evaluation
• Female
• Humans
• Infant
• Male
• Medulloblastoma (drug therapy)
• Neoplasm Recurrence, Local (drug therapy)
• Seizures (chemically induced)
• Vincristine (adverse effects, therapeutic use)